Rapport Therapeutics will report Phase 2a trial results for RAP-219 on September 8, 2025, via conference call.
Quiver AI Summary
Rapport Therapeutics, Inc. will host a conference call and live webcast on September 8, 2025, at 8:00 am ET to discuss topline results from the Phase 2a trial of its drug RAP-219, aimed at treating drug-resistant focal onset seizures. The company, which focuses on developing precision medicines for neurological and psychiatric disorders, utilizes a unique RAP technology platform based on groundbreaking research related to receptor associated proteins in the brain. RAP-219 is part of a wider pipeline that includes investigational treatments for conditions such as bipolar mania and diabetic peripheral neuropathic pain, along with other preclinical programs targeting chronic pain and hearing disorders. Investors can participate in the call through a provided link or by phone. A replay of the webcast will be accessible on the company's website for 90 days post-call.
Potential Positives
- Announcement of a conference call to report topline results for the Phase 2a trial of RAP-219 indicates transparency and engagement with investors.
- RAP-219 targets drug-resistant focal onset seizures, addressing an unmet need in neurological treatment options, which may drive interest and investment.
- The company’s unique RAP technology platform highlights innovative approaches in drug discovery, potentially positioning Rapport as a leader in precision medicine for neurological disorders.
- The presence of additional preclinical and late-stage discovery programs suggests a robust pipeline, enhancing the company's long-term growth prospects.
Potential Negatives
- None
FAQ
What is the purpose of the upcoming conference call by Rapport Therapeutics?
Rapport Therapeutics will discuss topline results for the Phase 2a trial of RAP-219 in drug-resistant focal onset seizures.
When will the conference call take place?
The conference call is scheduled for September 8, 2025, at 8:00 am ET.
How can I access the live conference call?
Listeners can join the call through a webcast link or by dialing specific phone numbers with conference ID 4762775.
Where can I find a replay of the conference call?
A replay will be available for 90 days in the "Investors" section of Rapport Therapeutics' website.
What is RAP-219 developed for?
RAP-219 is being developed for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RAPP Insider Trading Activity
$RAPP insiders have traded $RAPP stock on the open market 10 times in the past 6 months. Of those trades, 3 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $RAPP stock by insiders over the last 6 months:
- DAVID BREDT (Chief Scientific Officer) has made 0 purchases and 7 sales selling 51,000 shares for an estimated $594,727.
- TROY A. IGNELZI (Chief Financial Officer) has made 2 purchases buying 10,000 shares for an estimated $100,988 and 0 sales.
- WENDY B. YOUNG purchased 6,000 shares for an estimated $61,249
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RAPP Analyst Ratings
Wall Street analysts have issued reports on $RAPP in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JMP Securities issued a "Market Outperform" rating on 04/08/2025
To track analyst ratings and price targets for $RAPP, check out Quiver Quantitative's $RAPP forecast page.
$RAPP Price Targets
Multiple analysts have issued price targets for $RAPP recently. We have seen 2 analysts offer price targets for $RAPP in the last 6 months, with a median target of $29.5.
Here are some recent targets:
- Douglas Tsao from HC Wainwright & Co. set a target price of $31.0 on 08/06/2025
- Jason Butler from JMP Securities set a target price of $28.0 on 07/08/2025
Full Release
BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00 am ET on September 8, 2025, to report topline results for the Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures.
Individuals interested in listening to the live conference call may do so through this webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other locations and reference conference ID 4762775. A webcast replay will be available from the “Investors” section of the Company’s website here for 90 days following the completion of the call.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for drug-resistant focal onset seizures, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
[email protected]
